TB-500 vs AOD-9604: How These Two Research Peptides Actually Compare

Q: Does AOD-9604 help with tissue repair like TB-500?

There is no research base for that. AOD-9604 was developed and studied for fat metabolism, not tissue repair, wound healing, or tendon injury. Its inclusion alongside TB-500 in vendor recovery stack marketing is not supported by its own clinical research history.

Q: Which compound has stronger human evidence, TB-500 or AOD-9604?

AOD-9604 has a larger human clinical trial record, six trials and 925 patients, though that record shows a discontinued program due to lack of efficacy rather than a positive result. TB-500's human evidence is much thinner and mostly limited to related thymosin beta-4 drug candidates rather than TB-500 itself.

> Research disclaimer: This article compares publicly available research and regulatory information on thymosin beta-4 (TB-500) and AOD-9604, for informational purposes only. Neither compound is FDA-approved for human therapeutic use. Nothing here is medical advice, a dosing recommendation, or a protocol suggestion.

TB-500 vs AOD-9604: The Short Answer

TB-500 and AOD-9604 are grouped together on research-peptide vendor sites mainly because they're both sold in that market, not because they address the same biological question. TB-500 is a synthetic fragment of thymosin beta-4, an actin-regulating protein studied for its role in cell migration, tissue repair, and blood vessel formation. AOD-9604 is a modified fragment of the C-terminal region of human growth hormone (hGH), developed specifically to isolate hGH's fat-metabolizing activity from its growth-promoting and insulin-antagonizing effects. One is a tissue-repair research candidate; the other is a fat-metabolism research candidate with an unusually well-documented, and ultimately unsuccessful, human clinical trial history. Treating them as interchangeable "recovery peptides" misses what each was actually built to do.

What AOD-9604 Actually Is

AOD-9604 traces back to research at Monash University in Australia in the early 1990s. Researchers Frank Ng and colleagues were investigating whether the lipolytic (fat-metabolizing) activity of full-length human growth hormone could be separated from its other effects — specifically its growth-promoting action and its tendency to interfere with insulin signaling. In a 1993 paper, Wu and Ng showed that a synthetic version of the hGH C-terminal sequence spanning amino acid residues 177 to 191 reproduced the antilipogenic (fat-storage-inhibiting) activity of intact growth hormone in rat adipose tissue, without needing the rest of the hGH molecule.

The Australian biotechnology company Metabolic Pharmaceuticals subsequently developed a stabilized version of that 191-amino-acid fragment by adding a tyrosine residue at the N-terminus, producing the molecule now designated AOD-9604 (the name stands for Anti-Obesity Drug, compound 9604). The company pursued it as a candidate obesity drug through the 2000s, positioning it around the idea of a growth-hormone-derived compound that could target fat metabolism without the side effects associated with administering full hGH.

The Clinical Trial History Is the Most Distinctive Thing About AOD-9604

This is where AOD-9604 genuinely diverges from most peptides discussed on research-chemical vendor sites, including TB-500: it has an actual, well-documented human clinical trial record. Metabolic Pharmaceuticals ran six human clinical studies involving a combined 925 patients, evaluating AOD-9604 as an obesity treatment. The trials established that the compound was well-tolerated with no significant safety signal — an unusually strong safety record for a peptide in this category. What the trials did not show was a clinically meaningful weight-loss effect across the overall trial population, despite encouraging preclinical data. As a result, Metabolic Pharmaceuticals terminated the obesity development program in February 2007.

That trial outcome is worth sitting with, because it's a useful contrast case for interpreting preclinical peptide research generally. Rodent studies of AOD-9604 consistently showed reduced fat mass and increased fat oxidation, and those preclinical results looked strong enough to justify a substantial, well-funded human trial program. The effect simply didn't replicate at a clinically significant level once tested properly in humans, at scale, with a placebo control. TB-500's research base — covered throughout this site, including in our mechanism of action guide — remains almost entirely preclinical, meaning it hasn't yet gone through the stage where AOD-9604's promising animal data ran into disappointing human results. That's not a claim that TB-500 will or won't follow the same pattern; it's a reason to treat animal-model findings for any peptide, including TB-500, as suggestive rather than predictive of human outcomes. Our human clinical trials research overview covers the current, much thinner human evidence picture specific to TB-500.

Mechanism of Action: Where They Genuinely Diverge

The two compounds work through unrelated biological pathways:

1. TB-500 (thymosin beta-4 fragment). Works primarily through actin sequestration — binding G-actin and influencing how cells reorganize their cytoskeleton to migrate toward damaged tissue. This mechanism underlies the research on tendon and muscle repair, wound healing, and angiogenesis discussed across this site, including our angiogenesis research overview.

2. AOD-9604 (hGH fragment 177-191). Works by mimicking a specific region of the growth hormone molecule responsible for stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage), reportedly through upregulation of beta-3 adrenergic receptor activity in fat tissue. Critically, it was engineered to exclude the region of hGH responsible for growth-promoting (IGF-1-mediated) effects and insulin resistance — the properties that make administering full-length growth hormone more complicated from a safety standpoint.

There's no meaningful mechanistic overlap between actin-mediated cell migration and adrenergic-receptor-mediated fat metabolism. A study result for one doesn't inform expectations for the other, despite both compounds sometimes appearing side by side under a generic "research peptides" banner in vendor catalogs.

Regulatory and Legal Status Compared

Both compounds occupy the same broad "unapproved, research-use-only" category in the U.S. retail research-chemical market, but their regulatory histories differ in an important way. AOD-9604 actually went through a formal drug-development pathway — investigational new drug status, multi-phase human trials, a defined sponsor (Metabolic Pharmaceuticals) — and was discontinued specifically because the human efficacy data didn't support continued development, not because of a safety or legal action against it. TB-500 has never entered a comparable human drug-development pathway under its own name; the closest analog is thymosin beta-4's use in RegeneRx's separate ophthalmic and dermatological drug candidates, which is a different regulatory story covered in our TB-500 legal status overview.

Neither compound is FDA-approved for any human use, and neither is a controlled substance in the U.S. Both are sold under research-use-only labeling. Anyone evaluating either compound's regulatory standing should treat "was studied in six human trials and discontinued for lack of efficacy" and "has never been tested in a human trial under its own name" as genuinely different evidentiary positions, even though both currently result in the same retail research-chemical status.

Where the Comparison Breaks Down in Vendor Marketing

Vendor and forum content sometimes lists AOD-9604 alongside TB-500 and BPC-157 as a generic "recovery and body composition stack," which conflates three compounds with distinct, non-overlapping research bases. AOD-9604's research focus is specifically fat metabolism in the context of a discontinued obesity drug program; it was never developed or studied for tendon repair, wound healing, or the tissue-regeneration questions that TB-500's preclinical literature addresses. Framing AOD-9604 as a "recovery peptide" in the same category as TB-500 isn't supported by the compound's own development history — it was built and tested for an entirely different physiological target.

What's Still Unknown

Whether AOD-9604's preclinical fat-metabolism effects would replicate under a different trial design, dose, or population than Metabolic Pharmaceuticals tested has not been re-examined in a comparably sized human study since the 2007 program ended.

No published research has evaluated TB-500 and AOD-9604 in combination, despite both appearing together in some vendor stack marketing.

The extent to which AOD-9604's documented human safety profile (from the six-trial program) generalizes to the research-use-only material currently sold by peptide vendors — as opposed to the pharmaceutical-grade material used in Metabolic Pharmaceuticals' trials — has not been independently verified.

Frequently Asked Questions

Is AOD-9604 the same type of peptide as TB-500?

No. TB-500 is a fragment of thymosin beta-4, an actin-regulating protein studied for tissue repair and cell migration. AOD-9604 is a modified fragment of human growth hormone, studied specifically for fat metabolism. They are chemically and mechanistically unrelated.

Has AOD-9604 been tested in humans?

Yes, more extensively than TB-500. Metabolic Pharmaceuticals ran six human clinical trials involving 925 patients evaluating AOD-9604 as an obesity treatment. The compound was well-tolerated, but the trials didn't show a clinically meaningful weight-loss effect, and the program was discontinued in February 2007.

Does AOD-9604 help with tissue repair like TB-500?

There's no research base for that. AOD-9604 was developed and studied for fat metabolism, not tissue repair, wound healing, or tendon injury. Its inclusion alongside TB-500 in vendor "recovery stack" marketing isn't supported by its own clinical research history.

Which compound has stronger human evidence, TB-500 or AOD-9604?

AOD-9604 has a larger human clinical trial record — six trials, 925 patients — though that record shows a discontinued program due to lack of efficacy, not a positive result. TB-500's human evidence is much thinner and mostly limited to related thymosin beta-4 drug candidates rather than TB-500 itself; see our human clinical trials overview for that distinction.

Can TB-500 and AOD-9604 be combined?

Some vendor stack marketing pairs them, but no published study has tested the combination. Each compound's evidence base is independent, and the compounds target unrelated biological pathways, so there's no mechanistic research basis for expecting a combined effect.

Sourcing Quality TB-500 for Research

Comparing research peptides only matters if the material being studied is verifiably what the label claims. Apollo Peptide Sciences publishes third-party HPLC testing and certificates of analysis for its TB-500. See our peptide buying guide for what to verify before sourcing any research compound.

---